Ultrasound technology developer Echosens has appointed Romain Baujard as group CEO, effective May 1, 2026.
Baujard will succeed Dominique Legros, who will retire after leading the company since 2019.
Baujard joined Echosens in 2015 and most recently served as vice president of pharma, having previously held roles overseeing global marketing, international commercial operations, and pharmaceutical partnerships, according to the company. Under Legros, Echosens expanded its FibroScan noninvasive liver assessment technology beyond hepatology and gastroenterology into diabetology, endocrinology, and primary care.
